ClinicalTrials.gg
CompletedNCT06091943Updated Aug 12, 2026

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 1 interventional study of Tislelizumab IV and Tislelizumab SC in Non-small Cell Lung Cancer, sponsored by BeiGene. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
16th of 41
62 · median 39
Started
2023
with 5 others
Phase 1
2 of 41
none open now
Registered
24th of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 6 that started in 2023, is one of 2 in phase 1, and was the 24th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung cancer (NSCLC). This clinical study will be divided into 2 parts: dose/injection site exploration (Part 1) and dose expansion (Part 2).

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • lung cancer
  • non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to sign a written consent form, understand, and agree to comply with requirements of the study.
  • Documented locally advanced or recurrent NSCLC that is not eligible for curative surgery and/or definitive radiotherapy, with or without chemotherapy, or non-squamous or squamous NSCLC.
  • No prior systemic treatment for advanced or metastatic NSCLC, including but not limited to chemotherapy or targeted therapy.
  • At least one as assessed by v1.1.
  • (ECOG) PS ≤ 1.
  • Adequate organ function as indicated by laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed with NSCLC that harbor a driver mutation (eg, EGFR-sensitizing mutation, ALK fusion oncogene, and BRAF V600E mutation or ROS1 mutation).
  • Participant has received any Chinese herbal medicine or Chinese patent medicines used to control cancer within 14 days before first dose of study drug.
  • Active or uncontrolled, untreated .
  • Active diseases or history of autoimmune diseases that may relapse.
  • Any cancer ≤ 5 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, localized prostate cancer, carcinoma in situ of the cervix or breast).
  • Any condition that required systemic treatment with either (> 10 mg daily of prednisone or equivalent) or other medication ≤ 14 days before first dose of study drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part 1: Dose/Injection Site Exploration

    Different injection sites will be evaluated; participants will receive tislelizumab in predefined administration sequences plus histology-based chemotherapy consisting of either cisplatin/carboplatin and pemetrexed or carboplatin and paclitaxel/nab-paclitaxel depending on the cancer subtype.

    Drug: Tislelizumab IV · Drug: Tislelizumab SC · Drug: Histology-Based Chemotherapy Doublet

  • Experimental
    Part 2: Dose Expansion

    The recommended dose of tislelizumab SC determined from Part 1 plus histology-based chemotherapy consisting of either cisplatin/carboplatin and pemetrexed or carboplatin and paclitaxel/nab-paclitaxel depending on the cancer subtype will be evaluated.

    Drug: Tislelizumab SC · Drug: Histology-Based Chemotherapy Doublet

Interventions

  • Planned doses will be administered intravenously.

    Also known as: BGB-A317 IV

  • Planned doses will be administered via subcutaneous injection.

    Also known as: BGB-A317 SC

  • DrugHistology-Based Chemotherapy Doublet

    Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed. Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel. Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.

06

What researchers measure

Primary outcomes

  1. Part 1 and 2: Area under the concentration-time curve (AUC) of Tislelizumab SC

    Time frame: Up to approximately 3.5 months

  2. Part 1 and 2: Concentration at the end of dosing interval (Ctrough) of Tislelizumab SC

    Time frame: Up to approximately 3.5 months

  3. Part 1: Bioavailability of Tislelizumab SC

    Time frame: Up to approximately 2 months

  4. Part 2: Maximum observed plasma concentration (Cmax) of Tislelizumab SC

    Time frame: Up to approximately 3.5 months

  5. Part 2: Accumulation ratio (Rac) of Tislelizumab SC

    Time frame: Up to approximately 3.5 months

  6. Part 2: Elimination half-life (t1/2) of Tislelizumab SC

    Time frame: Up to approximately 3.5 months

  7. Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs and laboratory abnormalities, reported during the AE reporting period and characterized by type, frequency, severity (as graded by National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0 \[NCI-CTCAE v5.0\]), timing, seriousness, and relationship to study therapy.

    Time frame: Up to approximately 27 months

Secondary outcomes

  1. Part 1: Maximum observed concentration (Cmax) of Tislelizumab SC

    Time frame: Up to approximately 2 months

  2. Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs and laboratory abnormalities, reported during the AE reporting period and characterized by type, frequency, severity (as graded by NCI-CTCAE v5.0), timing, seriousness, and relationship to study therapy.

    Time frame: Up to approximately 27 months

  3. Part 1 and 2: Number of Participants with Anti-Tislelizumab Antibodies

    Time frame: Up to 25 months

  4. Part 2: Overall Response Rate (ORR) of Tislelizumab SC

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as determined from tumor assessments by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

    Time frame: Up to approximately 27 months

  5. Part 2: Duration of Response (DOR) of Tislelizumab SC

    DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death due to any cause, whichever occurs first as assessed by the investigator.

    Time frame: Up to approximately 27 months

  6. Part 2: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 27 months

07

Study locations

15 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian 350025, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Jining No Peoples Hospital East Branch
    Jining, Shandong 272002, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • Deyangs People Hospital
    Deyang, Sichuan 618000, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang 313003, China
  • Arensia Exploratory Medicine Llc
    Tbilisi, 0112, Georgia
  • The Institute of Oncology, Arensia Exploratory Medicine
    Chisinau, 2025, Moldova
08

References and documents

Publications

  • Liu X, Guan Y, Liu Y, Yu T, Abdrashitov R, Niu Z, Lin X, Ye X, Wang Y, Sahasranaman S, Hanley WD, Budha N. Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. Clin Transl Sci. 2026 Jul;19(7):e70649. doi: 10.1111/cts.70649. PubMed 42337921 ↗

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2025, 20 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 20 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartActual
Nov 16, 2023
Primary completionActual
Jul 31, 2025
CompletionActual
Aug 4, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091943
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Nov 16, 2023
Primary completion
Jul 31, 2025
Completion
Aug 4, 2026
Last update
Aug 12, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion